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Unveiling the “Three Finger Pharmacophore” required for p53-
MDM2 Inhibition by Saturation Transfer Difference NMR Initial 
Growth Rates Approach 
 
Jesus Angulo*,[a] Sarah A. Goffin, [a] Daivik Gandhi, [a]   Mark Searcey[a,b]  and Lesley A. Howell*[a] 
 
Abstract: Inhibitors of the p53-MDM2 protein-protein interaction are 
emerging as a novel and validated approach to treating cancer. In 
this work we describe the synthesis and inhibitory evaluation of a 
series of isoquinolin-1-one analogues, and highlight the utility of an 
initial growth rates STD NMR approach supported by protein-ligand 
docking to investigate p53-MDM2 inhibition. The approach is 
illustrated by the study of compound 1, providing key insights into 
the binding mode of this kind of MDM2 ligands and, more importantly, 
readily unveiling the previously proposed three finger 
pharmacophore requirement for p53-MDM2 inhibition. 
Protein-protein interactions (PPIs) had been considered 
“undruggable” primarily due to large surface areas and their flat, 
featureless and hydrophobic nature.[1–3] However, the success of 
small molecule inhibitors such as the Nutlins,[4] p53-MDM2 
inhibitors and Navitoclax,[5,6] a dual inhibitor of Bcl-2 and Bcl-xL 
(both of which are currently in clinical trials) have defied this 
view point. PPIs still pose a considerable challenge to the 
medicinal chemistry community, but they are an attractive drug 
target due to their ability to modulate outcomes within cells, 
hence allowing greater control than classical drug targets such 
as enzymes or receptors.[7,8] The most widely studied PPI is the 
p53-MDM2 paradigm.[9] The tumour suppressor protein p53 is a 
key transcription factor involved in regulating the cell cycle and 
apoptosis.[10] It is often referred to as the guardian of the 
genome[11] and plays a crucial role in cancer; nearly all tumours 
show a defect in the p53 gene itself or in other negative 
regulatory proteins such as MDM2 or MDMX.[12] In cancer cells 
with wt-p53, over expression of either MDM2 and/or MDMX 
supresses p53 activity and disrupts the apoptosis pathway.[13] 
Therefore the restoration of the p53 pathway, by inhibiting the 
p53-MDM2 interaction with small molecules, represents an 
attractive and viable approach to treating cancer. 
 NMR is one of the most powerful spectroscopic techniques 
to study biomolecular interactions and has been applied to the 
discovery of protein-protein inhibitors,[14] some of them focused 
on the MDM2-p53 interaction.[15–17] In particular, Holak and co-
workers recently devised a smart 2D 1H,15N NMR based method 
to test inhibition of PPIs, called AIDA, that they also applied to 
the MDM2-p53 interaction.[18,19] However, although that method 
provides relevant information about the protein residues of 
MDM2 involved in binding, the information about the bioactive 
conformation and the mode of binding of the ligand is lost. This 
kind of structural information is attainable by saturation transfer 
difference (STD) NMR spectroscopy,[20–22] if a thorough 
quantitative analysis of the experiments is carried out by means 
of the STD build-up curves.[23–25] 
 Herein we report the synthesis of a series of isoquinolin-1-
one analogues, their p53-MDM2 inhibitory activity as determined 
using a fluorescence polarisation assay, and a STD NMR initial 
growth rates approach to identify the binding mode of one of the 
lead compounds.  Notably, the results suggest that STD NMR is 
an easy and powerful tool to verify the proposed three finger 
pharmacophore requirement for p53-MDM2 inhibition, providing 
in addition key structural information regarding its interactions 
with the hydrophobic groove of MDM2, for future lead 
optimisation. 
 Our previous work on p53-MDM2 inhibitors has involved 
the natural product chlorofusin[26,27] and more recently the 
identification of a novel small molecule inhibitor inspired by our 
studies of this natural product.[28] Of late we have been working 
on producing a library of isoquinolin-1-one analogues. 
Isoquinoline-1-ones have been shown to inhibit the p53-MDM2 
PPI with low micromolar activity. [29] We sought to develop a 
procedure by which a relatively large number of diverse 
compounds could be synthesised quickly with minimum 
purification to identify potent small molecule inhibitors of the 
p53-MDM2 interaction.  
 A modified Castagnoli reaction was employed to 
synthesise the isoquinolin-1-ones.[30] The reaction involves the 
condensation of a Schiff base with an acid anhydride (scheme 1). 
Briefly a stoichiometric amount of a benzyl amine and an 
aldehyde were reacted together under anhydrous conditions in 
the 
prese
nce 
of 
magn
esiu
m 
sulphate to form the corresponding  
Scheme 1 Synthesis of isoquinolin-1-ones  
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imine. The reactions reached completion in 2-4 hours (as shown 
by TLC), after which the solutions were filtered. The filtrate was 
then added to 1 equivalent of homophthalic anhydride and the 
reaction left overnight at room temperature. The resultant 
precipitate was filtered, washed with hot ethyl acetate and dried 
in vacuo. Those compounds that did not precipitate were 
evaporated and purified via flash column chromatography. A 
total of 60 compounds were prepared in this manner (see ESI). 
The reaction can produce either the cis or trans isomers or a 
mixture of both with the major diastereoisomer expected to be 
the more thermodynamically stable trans product.[31] 
 We had originally assumed the reaction would proceed 
racemically and initially proposed to evaluate the compounds as 
racemic mixtures. However, on further investigation we found 
the reaction did indeed exhibit some stereocontrol as the 
compounds were found to be optically active. Looking into the 
literature there is some precedent for stereocontrol for this class 
of reaction: the condensation of o-anisylidenemethylamine with 
glutaric anhydride yields the trans piperidone product as the 
major diastereoisomer with the aromatic ring occupying the axial 
position essentially fixing the stereochemistry at this carbon.[32]  
This is a result of the planar nature of the amide bond. 
Presumably this is further enhanced in our molecules due to the 
additional planar benzene fused to the piperidone resulting in 
only one enantiomer formed as the major product. An alternative 
explanation for the observation of only one enantiomer is 
preferential crystallisation, also known as resolution by 
entrainment, whereby the resolution is performed without the 
use of a resolving agent.[33]  
 The compounds were screened using a fluorescence 
polarisation (FP) assay described previously.[28] Human MDM2 
protein (17-125) was used in the polarisation assay and the 
wildtype p53 peptide (residues 15–27) was used as a positive 
control and had an IC50 of 14.45 µM and Ki of 1.82 µM. 
Screening the isoquinolin-1-ones at 100 µM concentration 
revealed seven hits which were further evaluated over a wider 
concentration range to determine their IC50’s (Table 1). 
Interestingly all seven compounds were found to be the trans 
isomer and all were substituted with halogens indicating the 
importance of halides for MDM2 binding ligands. Compound 7 
was the most active with low micromolar activity with compounds 
2, 5 and 6 exhibiting similar activity to wild type p53.  
 We chose compound 1 as our model compound for the 
NMR binding study. Due to the structural similarity of 1-7, 
comparable binding modes for all could be foreseen, and we 
then decided to test one of the weakest ligands, as STD NMR 
requires a binding kinetics falling within the so-called fast 
exchange conditions (Ki values in Table 1 suggest these 
molecules might fall at the limits of the technique). Within the 
weakest binders (1, 3, and 4) we selected 1, as it was the most 
potent inhibitor (lowest Ki). The binding of 1 to human MDM2 in 
solution was confirmed by STD NMR (Figure 1). Strong 
saturation transfer signals were observed in the difference 
spectrum (Figure 1, bottom). Besides providing a proof of 
binding, structural information was obtained by a complete 
kinetics study of the evolution of STD intensities with the 
saturation time of the protein. Briefly, the STD intensities were 
determined at different saturation times (STD build-up curves), 
and the initial growth rates of each curve were obtained by 
mathematical fitting; those initial slope values were then used to 
map out the ligand epitope (see ESI).[24] The presence of 
aromatic rings in combination with saturated residues (e.g. 
aliphatics) in most of the structures of protein-protein inhibitors 
(as in the case of 1) makes this approach very suitable, as 
“aromatic ring – protein” contacts can be overstated if a single 
large saturation time is employed, instead of a whole build-up 
analysis.[34] 
 The initial growth rates of the curves were determined 
using a monoexponential model (see ESI) and their relative 
distribution among the protons of 1 was calculated to map out 
the binding epitope of the ligand for binding to human MDM2 
(normalised STD values in Figure 2). The binding epitope of 1 
(Figure 2) revealed significant structural information about the 
molecular recognition of this kind of compound by human MDM2. 
The three aromatic residues of 1 constitute the main spatial 
contacts with the protein in the bound state, with the chloride 
substituted phenyl ring (R1 in scheme 1) showing the closest 
contacts. In contrast, the six- membered ring tethering the 
aromatic residues together showed the lowest STD intensities, 
along with the methylene bridge protons linking the fluoride 
substituted phenyl ring (Figure 2, in blue). The differences in 
relative STD values, although small, are significant, as they 
correspond to a slow kinetics  (low micromolar) binder, for the 
standards of STD NMR, and for that reason the criterion to split 
STD intensities in strong and weak was raised up to a level of 
80% relative STD (Figure 2). The firmness of the interpretation 
of the binding epitope of 1 relies on the accuracy of the STD 
initial growth rates approach followed on this work (see ESI). 
 In solution, 1 binds human MDM2 mainly through the 
apolar aromatic moieties, which is compatible with the largely 
hydrophobic character of the amino acid residues lining the p53-
binding site of human MDM2. The most polar part of 1 (the 
central six-membered ring and the methylene bridge) makes 
fewer  
 
Figure 1. Expanded view of the aromatic region of the STD NMR (298 K, 800 
MHz, 1 s saturation time) of a sample containing an excess of 1 (1 mM 
concentration) over the protein MDM2 (20 uM). The top spectrum corresponds 
to the equilibrium intensities of 1 (1D reference 
1
H NMR spectrum) whereas 
the bottom one shows the difference spectrum, in which the intensities 
corresponds to transfer of magnetization from the protein upon binding (most 
intense STD signals highlighted in the spectrum and on the chemical formula 
of 1, inset at the top). 
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contacts with the protein and is accordingly more solvent 
exposed in the bound state. This mode of binding is reminiscent 
of that of some previously described MDM2-p53 inhibitors, 
strongly supporting that the initial growth rates STD NMR 
approach can be used a simple technique to unveil the so-called 
“three finger pharmacophore” requirement for MDM2-p53 
inhibition (Figure 2).[9]  
 To get a 3D molecular model of the interaction of 1 with 
human MDM2 we carried out docking calculations using the 
program Glide.[35,36]  We used the published Cartesian 
coordinates of the protein (pdb entry: 1T4E) in complex with a 
benzodiazepinedione.[37] The original ligand was removed and 
docking calculations were run with ligand 1. Although we knew 
the ligand sample (without MDM2) had optical activity, by NMR it 
was not possible to elucidate which enantiomer was in excess. 
For that reason we carried out the docking calculations with both 
enantiomers. Interestingly, the 3R,4R-enantiomer led to the 
energetically most favourable docking solution, which in addition 
was in excellent agreement with the experimental STD NMR 
data (Figure 3). For the 3S,4S enantiomer, the best scored 
docking solution was much higher in energy (above 17 kcal/mol), 
and gave very poor agreement with the experimental STD NMR 
data (see ESI). In this way, the combined protocol of STD initial 
growth rates and docking calculations allowed us to identify the 
3R,4R-enantiomer as the most active for MDM2 in solution. The 
best-scored docking pose for the 3R,4R- enantiomer was further 
energy minimized and the solution is shown in Figure 3. 
 A comparison of Figures 2 and 3 demonstrates that the 3D 
docking molecular model of 1 bound to human MDM2 agrees 
remarkably well with the experimental NMR results in solution 
state. The three aromatic residues of 1 make close contacts with 
the protein in the bound state, with a higher predominance of 
contacts with amino acids with hydrophobic side chains (see 
map of protein-ligand contacts in the ESI). The chlorine 
substituted phenyl ring is buried in an internal cavity between 
GLY58 and LEU54, explaining the largest amount of saturation 
transferred from the protein in the NMR spectra. The carboxylate  
group as well as the methylene bridge are pointing towards the 
solvent, which agrees very well with the observed lower STD 
intensities. 
 
 
Figure 2 Binding epitope of 1 to the protein MDM2 as obtained by STD NMR. 
The values indicate normalized STD values for each proton of 1. The highest 
values results from very close contacts of the ligand to the MDM2 surface in 
the bound state (red), whereas the smallest ones indicate regions of 1 being 
solvent exposed. 
 The STD NMR initial growth rates approach and the 
modelling study of 1 has provided very relevant structural 
information about the molecular recognition of this series of 
ligands by the human MDM2 receptor. In this way, further 
improvement of human MDM2 ligands should exploit this 
information; e.g. modifications must be on those parts of the 
ligands making fewer contacts with the protein (carboxylate and 
methylene bridge). Indeed an analogue substituted on the 
methylene bridge with a methyl alcohol inhibited the PPI with an 
IC50 of 15.01 µM. This is also in agreement with the previous 
study by Holak and co-workers, as they showed that changing 
the carboxylate of similar compounds to an amide spacer did not 
affect the affinity.[29] Interestingly, the comparison of the binding 
mode of 1 with the published structure of the complex with the 
benzodiazepinedione ligand (see ESI), further highlights the two 
pending halogenated aromatic residues as being the most 
important elements for molecular recognition. In the case of the 
benzodiazepinedione ligand,[37] the fused aromatic ring bears a 
bulky iodine atom that pushes it farther from the protein surface 
than in the case of 1, so that the fused aromatic ring of 1 falls in 
a significantly shifted position, compared to that ligand, which 
supports that the molecular recognition is not specific for that 
moiety. Yet, the matching of the two halogenated aromatic rings 
of 1 with the published benzodiazepinedione structure is 
excellent (see ESI). 
In conclusion we have reported the synthesis of a library of 
isoquinolin-1-ones as potential inhibitors of the p53-MDM2 
protein-protein interaction. Seven compounds were identified 
with IC50’s in the low micromolar range. One of the compounds, 
1, was explored further using STD NMR to determine its binding 
epitope for the hydrophobic groove of human MDM2. These 
studies have shown the power of the initial growth rates STD 
NMR approach applied to biologically relevant PPIs. In the 
particular case of the p53-MDM2 interaction, the approach has  
 
Table 1. Binding of compounds 1-7 to MDM2 using the fluorescence 
polarisation assay.
 
 
Compound R1 R2 IC50 (µM)
[a]
 Ki (µM)
 [b]
 
1 4-ClPh 4-F 56.6 7.13 
2 4-BrPh 4-F 19.8 2.49 
3 4-IPh 4-F 57.7 7.29 
4 4-ClPh 4-Cl 61.2 7.71 
5 4-BrPh 4-Cl 21.3 2.68 
6 4-ClPh 4-Br 27.1 2.36 
7 4-BrPh 4-Br 6.6 0.83 
[a] Concentration of substrate required to decrease polarization fluorescence 
by 50%. Experiments performed in triplicate. [b] Apparent inhibition constant. 
Experiments performed in triplicate. 
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Figure 3 3D molecular model of the complex of 1 with human MDM2. (a) 
Bound conformation (best docking pose) of 1 in the p53-binding pocket of 
MDM2.  (b) Mesh representation of the MDM2 surface closest to non-polar 
hydrogens of 1 in the bound state (those observable in STD NMR). The 
energetically most favourable docking solution (enantiomer 3R,4R) 
qualitatively gives an excellent agreement with the observed STD NMR 
intensities. 
demonstrated to be very useful for verifying the three finger 
pharmacophore requirement of small molecules for inhibition, 
without the need for isotopic labelling of the protein, and using 
small sub-stoichiometric amounts of the receptor. The analysis 
of the whole STD build-up curve (initial growth rates) is 
mandatory as typical PPI inhibitors contain protons with different 
relaxation properties that could lead to misinterpreted epitopes if 
a single “one-saturation time” experiment were used. Recently, a 
novel type of p53-MDM2 inhibitor, based on 6-chloroindole 
scaffolds, has demonstrated that the “plasticity” of the p53-
binding site on MDM2 allows some small molecules to show an 
extended four-point pharmacophore model;[38] the STD NMR 
approach followed here will be a powerful and simple method for 
distinguishing between both (3- or 4-finger) pharmacophore 
modes of binding for novel generations of MDM2 ligands. We 
envisage an increased use of the STD NMR initial growth rates 
approach to the design of protein-protein inhibitors, to verify the 
pharmacophore, and to determine the structural requirements 
for molecular recognition, extremely valuable information for the 
improvement of the small molecule candidates to inhibit PPIs.  
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